These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8648202)

  • 1. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.
    Gruber WC; Belshe RB; King JC; Treanor JJ; Piedra PA; Wright PF; Reed GW; Anderson E; Newman F
    J Infect Dis; 1996 Jun; 173(6):1313-9. PubMed ID: 8648202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response.
    Gruber WC; Darden PM; Still JG; Lohr J; Reed G; Wright PF
    Vaccine; 1997; 15(12-13):1379-84. PubMed ID: 9302748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus.
    Feldman S; Wright PF; Webster RG; Roberson PK; Mahoney J; Thompson J; Doolittle M; Lott L; Johnson P; Christoph RC
    J Infect Dis; 1985 Dec; 152(6):1212-8. PubMed ID: 3905983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines.
    Gruber WC; Hinson HP; Holland KL; Thompson JM; Reed GW; Wright PF
    J Infect Dis; 1993 Nov; 168(5):1282-5. PubMed ID: 8228364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults.
    Sears SD; Clements ML; Betts RF; Maassab HF; Murphy BR; Snyder MH
    J Infect Dis; 1988 Dec; 158(6):1209-19. PubMed ID: 3198936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center.
    Clements ML; Makhene MK; Karron RA; Murphy BR; Steinhoff MC; Subbarao K; Wilson MH; Wright PF
    J Infect Dis; 1996 Jan; 173(1):44-51. PubMed ID: 8537681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial.
    Alexandrova GI; Budilovsky GN; Koval TA; Polezhaev FI; Garmashova LM; Ghendon YuZ ; Romanova YR; Smorodintsev AA
    Vaccine; 1986 Jun; 4(2):114-8. PubMed ID: 3524050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.
    Zangwill KM; Droge J; Mendelman P; Marcy SM; Partridge S; Chiu CY; Jing J; Chang SJ; Cho I; Ward JI
    Pediatr Infect Dis J; 2001 Aug; 20(8):740-6. PubMed ID: 11734734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
    Talaat KR; Karron RA; Callahan KA; Luke CJ; DiLorenzo SC; Chen GL; Lamirande EW; Jin H; Coelingh KL; Murphy BR; Kemble G; Subbarao K
    Vaccine; 2009 Jun; 27(28):3744-53. PubMed ID: 19464558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
    King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
    Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children.
    Steinhoff MC; Halsey NA; Wilson MH; Burns BA; Samorodin RK; Fries LF; Murphy BR; Clements ML
    J Infect Dis; 1990 Aug; 162(2):394-401. PubMed ID: 2197335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.
    Belshe RB; Swierkosz EM; Anderson EL; Newman FK; Nugent SL; Maassab HF
    J Infect Dis; 1992 Apr; 165(4):727-32. PubMed ID: 1552202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Cho I; Reisinger K; Block SL; Wittes J; Iacuzio D; Piedra P; Treanor J; King J; Kotloff K; Bernstein DI; Hayden FG; Zangwill K; Yan L; Wolff M
    J Pediatr; 2000 Feb; 136(2):168-75. PubMed ID: 10657821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses.
    Rodriguez L; Nogales A; Murcia PR; Parrish CR; Martínez-Sobrido L
    Vaccine; 2017 Aug; 35(34):4374-4381. PubMed ID: 28709557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults.
    Treanor JJ; Roth FK; Betts RF
    J Clin Microbiol; 1990 Mar; 28(3):596-9. PubMed ID: 2182673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
    Edwards KM; Dupont WD; Westrich MK; Plummer WD; Palmer PS; Wright PF
    J Infect Dis; 1994 Jan; 169(1):68-76. PubMed ID: 8277200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.
    Nolan T; Lee MS; Cordova JM; Cho I; Walker RE; August MJ; Larson S; Coelingh KL; Mendelman PM
    Vaccine; 2003 Mar; 21(11-12):1224-31. PubMed ID: 12559802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.